Abstract:Background: Pathophysiologic changes of posttransplant lung ischemia/reperfusion injury are mediated by redundant cellular and humoral mechanisms. We investigated the protective effect of combined administration of platelet activating factor (PAF) and endothelin (ET) antagonists after prolonged ischemia in a small animal lung transplantation model.Methods: Orthotopic left Lung transplantation was performed after 20 hours cold ischemia in male Fischer (F344) rats weighing 200-250 g. Group I served as control. Ih Group II, donors received 1 mg/kg body weight of the endothelin antagonist TAK-044, and recipients 2 mg/kg. Group III was treated with the PAF antagonist TCV-309 (donor: 50 mu g/kg; recipient: 100 mu g/kg) (Takeda Chemicals Ltd.). Group IV received a combined treatment with both substances at the same dosage. Twenty-four hours after reperfusion, the native contralateral lung was occluded to assess gas exchange of the graft only, and 5 minutes later the thoracic aorta was punctured for arterial blood gas analysis (n = 5). In other animals (n = 5), lung tissue was frozen 24 hours after reperfusion and assessed for myeloperoxidase activity (MPO) and thiobarbituric acid reactive substances.Results: Combined inhibition of PAF and ET-1 at the receptor level resulted in significantly improved graft function as compared to controls (Group I), and to groups treated with either TAK-044 or TCV-309. This was determined by a higher arterial oxygen content (112 +/- 9 mmHg, p = .00061 vs control, 48 +/- 5 mmHg), reduced MPO activity (0.35 +/- 0.02 Delta hOD/mg/min,p = .000002 vs control, 1.1 +/- 0.1 Delta OD/mg/min) and reduced lipid peroxidation (59.5 +/- 2.5 pmol/g, p = .011 vs control, 78.5 +/- 4.1 pmol/g). The improvement of arterial oxygen (Group II 77 +/- 10 mmHg, p = .027 vs control; Group III 84 +/- 8 mmHg, p = .0081 vs control) and reduction of MPO activity (Group II 0.85 +/- 0.061 Delta OD/mg/min,p = .017; Group III 0.92 +/- 0.079 Delta OD/mg/min, p = .058) in groups treated with either a PAF antagonist or an ET antagonist was significantly less than in Group IV.Conclusions: Combined donor and recipient treatment with an ET antagonist and a PAF antagonist results in superior posttransplant graft function 24 hours after reperfusion, suggesting a synergistic role of ET-1 and PAF in the mediation of reperfusion injury in this model. Single treatment with either of the antagonists revealed only a slight improvement compared to untreated controls.

Pentoxifylline Attenuates Platelet-Activating Factor-Induced Permeable Edema in Isolated-Perfused Guinea-Pig Lungs

Phospholipase A2-induced Lung Edema and Its Mechanism in Isolated Perfused Guinea Pig Lung.

Penehyclidine Hydrochloride Attenuates LPS-induced Acute Lung Injury Involvement of NF-kappaB Pathway.

Effect of hemoperfusion with adsorbents containing ser ligand for endotoxin removal on lung injuries in a porcine model of endotoxemia

The Role of Plateletactivating Factor in Hepatic Ischemiareperfusion Injury and the Protective Effect of Anisodamine

Systemic Evaluation of Platelet and Leukocyte Activation and Interaction in A Rat Model of Pulmonary Arterial Hypertension

PHC Inhibits Sequestration of Neutrophils and Activation of NF-kappa B in Lung Tissue of ALI Rats Induced by LPS

Therapeutic Effect of Intravenous Infusion of Perfluorocarbon Emulsion on LPS-Induced Acute Lung Injury in Rats

Effects of Anisodamine on the Injury of Rat Pulmonary Microvascular Endothelial Cells Induced by Platelet-Activating Factor

Pancreatitis-associated Pulmonary Injury: Effects of Lexipafant, a Platelet-Activating Factor Antagonist

Effects of pentoxifylline on inflammatory response to acute lung injury induced by LPS in rats

Pentoxifylline Regulates Plasminogen Activator Inhibitor-1 Expression and Protein Kinase A Phosphorylation in Radiation-Induced Lung Fibrosis

Early treatment with lexipafant, a platelet-activating factor-receptor antagonist, is not sufficient to prevent pulmonary endothelial damage after intestinal ischaemia and reperfusion in rats.

The Effects of Platelet-Activating-Factor and Retinoic Acid on the Expression of Elam-1 and Icam-1 and the Functions of Neutrophils

The Peptide DH α-(4-pentenyl)-ANPQIR-NH2 Exhibits Antifibrotic Activity in Multiple Pulmonary Fibrosis Models Induced by Particulate and Soluble Chemical Fibrogenic Agents

Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-kappa B pathways

Panax notoginseng saponin alleviates pulmonary fibrosis in rats by modulating the renin-angiotensin system

Inhibition of Inflammation and Regulation of AQPs/ENaCs/Na+-K+-ATPase Mediated Alveolar Fluid Transport by Total Flavonoids Extracted From Nervilia fordii in Lipopolysaccharide-induced Acute Lung Injury

Effect of a Platelet-Activating Factor Antagonist on Pancreatitis-Associated Gut Barrier Dysfunction in Rats.

Combined Treatment with Endothelin- and PAF-antagonists Reduces Posttransplant Lung Ischemia/reperfusion Injury.

Effect of platelet-activating factor acetylhydrolase on severe acute pancreatitis-induced lung injury in rats